Our goal was to examine whether Muslim patients with type 2 diabetes using SGLT2 inhibitors during the fasting month of Ramadan face an increased risk of volume depletion and assess its impact on renal function, focusing on safety concerns. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.